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Caprine arthritis encephalitis virus (CAEV) is a lentivirus which is closely related by nucleotide sequence and biological
properties to visna virus and is more distantly related to the human AIDS virus, HIV-1. Previous studies indicated that the
CAEV Rev protein (Rev-C) functions as a trans-activator of mRNA cytoplasmic transport and expression. The function of
Rev-C is mediated through an RNA element (RRE-C) present between nucleotides (nt) 7906 and 8110 in the CAEV env gene.
In this study, RNA/protein immunoprecipitation experiments were used to demonstrate that Rev-C binds directly to the 204-nt
RRE-C in vitro. Competition assays illustrate that this interaction is specific for the positive sense RRE-C RNA. Glutaraldehyde
crosslinking studies demonstrate that the wildtype Rev-C protein can also form multimeric complexes in vitro. Deletions or
amino acid alterations within the basic domain of Rev-C reduce affinity for the RRE and disrupt assembly of Rev-C multimers
in vitro, indicating that this domain is involved in RRE binding and Rev multimer formation. Mutations within the leucine-rich
domain of Rev-C do not greatly effect RRE-C binding or self-assembly. However, previous results demonstrate that some
leucine-rich domain mutants are unable to trans-activate. These data are consistent with the hypothesis that the leucine
domain is the effector domain of Rev-C. q 1996 Academic Press, Inc.
The lentiviruses are a subfamily of the Retroviridae RNA (gag and pol ) and from singly-spliced messages
(env) (1). The lentiviruses can be distinguished from otherthat are characterized by similarities in ultrastructure,
retroviruses by the presence of small open readinggenomic organization, and disease progression. These
frames (ORFs) in their genomes that encode regulatoryviruses typically cause chronic, multiorgan diseases that
proteins (Fig. 1A). The location and number of these smallare apparent only months to years after initial infection
regulatory genes vary between lentiviruses; the ovine(1). The most extensively studied lentivirus to date is
lentiviruses, CAEV and visna virus, express three differ-HIV-1 (human immunodeficiency virus 1), which causes
ent regulatory proteins (5, 6), while the more compleximmunodeficiency and neurological disease in humans
human lentivirus HIV-1 produces at least seven (7, 8).(1). Visna virus, the prototype nonprimate lentivirus, in-
Two of these nonstructural genes, tat and rev, have beenfects sheep and causes a chronic disease state charac-
found in all lentiviruses studied to date (9–16). Tat andterized by pneumonitis and progressive demyelination
Rev are both translated from small, multiply splicedwithin the central nervous system of the infected animal
mRNAs (Fig. 1A) and have been shown to be absolutely(2, 3). Caprine arthritis encephalitis virus (CAEV), which
required for replication of HIV-1, visna virus, and CAEVis closely related to visna virus, is a lentivirus of goats
in culture (17–19).that causes neurological disease in kids and chronic
Examination of HIV, visna virus, and CAEV gene ex-arthritis in adults (4 ).
pression at various times after infection has demon-Sequence analysis of lentiviral genomes demonstrates
strated that their genes are temporally regulated. Early
that they share similar genomic organization. Like other in infection, the small, multiply spliced mRNAs that en-
retroviruses, lentiviral genomes are flanked by long ter- code Tat and Rev predominate. Later during infection,
minal repeats (LTR) and contain the genes for the struc- the singly spliced and unspliced RNAs increase with a
tural proteins: gag (capsid proteins), pol (reverse tran- concomitant decrease in the levels of the multiply spliced
scriptase), and env (envelope glycoproteins). These RNAs (20, 21; R. Schoborg, unpublished results). Analysis
structural proteins are produced from full length genomic of Rev-deficient clones of HIV-1 and CAEV has indicated
that in the absence of the Rev protein, viral gene expres-
sion is trapped in the ‘‘early phase’’ in which only the1 To whom correspondence and reprint requests should be ad-
multiply spliced viral mRNAs are transported to the cyto-dressed at Quillen College of Medicine, Department of Microbiology,
Box 70579, Johnson City, TN 37614-0579. Fax: (423) 929-5847. plasm of an infected cell, indicating that Rev is required
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FIG. 1. Organization of the CAEV genome and amino acid sequence of the visna virus and CAEV Rev proteins. (A) Organization of the CAEV
genome and map of the Rev-C expressing cDNA clone. The open reading frames (ORFs) and LTRs of CAEV are represented by open boxes; the
identity of each is indicated. The exons of the Rev-C are represented by thick solid lines; introns are indicated by dashed lines. Splice donors are
indicated by SD; splice acceptor sites by SA. Numbering (bps) is with respect to the CAEV RNA genome with nucleotide (nt) / 1 being the RNA
cap site. (B) Amino acid sequence comparison of the visna virus and CAEV Rev proteins. The amino acids have been aligned for best fit. Amino
acid identity is indicated by a vertical line; amino acid similarity is denoted by single or double dots. The basic and leucine-rich domains are shown
in boxes. The C-terminal peptide used for production of the Rev-C specific antibodies is underlined with a dark bar (15, 19).
for cytoplasmic transport of lentiviral structural gene taining reporter construct (30). In addition, certain leucine
mRNAs (19, 22, 23). domain mutants of HIV and visna virus Rev can act as
The lentiviral mRNA processing/transport pathway re- dominant negative repressors of wildtype Rev function
quires at least two distinct elements in order to function: (26, 30). Recent studies have indicated that the leucine
(1) the Rev protein and (2) a discrete, structured RNA domain of Rev interacts with several cellular proteins
element called the Rev Response Element (RRE). The (32–34 ). This interaction is thought to direct the nuclear
Rev protein functions in trans by binding to the RRE; the Rev/ viral RNA complex to a nonmessenger RNA cyto-
RRE is present in the target RNA (23–25). Two domains plasmic transport pathway and, therefore, mediate Rev-
of the Rev protein are required for function (Fig. 1A); these dependent transport of RRE containing RNAs to the cyto-
are the basic and the leucine-rich domains. Mutation of plasm of the host cell (32–35).
basic amino acid residues (especially arginines) in the Another critical component of the Rev response sys-
HIV-1 Rev basic domain has severe affects upon its bio- tem is the RRE. The RREs of HIV, visna virus, and CAEV
logic function; in addition, in vitro RRE binding and multi- are RNA stem-loop structures that are located in the
merization activities of these mutants are often impaired env ORF of each virus (36–40). Comparison of the env
(26–30). The nuclear and nucleolar localization of many sequences of CAEV and visna virus followed by minimal
of these mutants is also diminished (29, 30). Similar muta- energy folding secondary structure analysis reveals a
tions within CAEV Rev (Rev-C) also decrease trans-acti- potential RNA stem-loop structure, similar to that of the
vating activity, alter subcellular localization, and elimi- HIV RRE, between nucleotide (nt) 7924 and nt 8125 of
nate function during viral infection (15, 19). visna virus and between nt 7906 and nt 8108 of the CAEV
The other essential domain of Rev is the activation (or genome (6, 40). Even though the predicted secondary
leucine-rich) domain. Deletion or mutation of the leucines structures of these regions are almost identical, they
in this domain inactivate the HIV, visna, and CAEV Rev share no clear sequence similarity (6). These regions of
proteins (15, 26, 30, 31). Mutation of two leucine residues visna virus and CAEV have been functionally defined as
at positions 112 and 114 (Fig. 1B) in the activation domain the target for their cognate Rev proteins using cotransfec-
greatly decreases the ability of the visna Rev protein tion assays (11, 15, 30).
In vivo analysis has indicated that both HIV-1 and visna(Rev-V) to trans-activate a visna virus RRE (RRE-V) con-
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virus Rev mediate their activity by binding to their cognate
RREs (23, 30, 40). In addition, both HIV and visna Rev
proteins have been shown to interact with their respec-
tive RREs in vitro (39–41). Since we previously localized
the RRE-C to nt 7906–8110 using functional assays, we
decided to test the ability of Rev-C and RRE-C to interact
specifically in vitro using an RNA binding/immunoprecipi-
tation assay (Fig. 2A). The RRE-C (nt 7906 to 8110) was
PCR amplified using specific oligonucleotides and
cloned into the unique KpnI site of the plasmid pGEM
7Z (Promega). This construct can be in vitro transcribed
to produce both positive (/) and negative (0) polarity
RRE-C transcripts. Human actin (nt 150 to nt 254; (42)),
visna tat (nt 5652 to 5944), visna env (nt 6486 to nt 6277),
and CAEV rev (CAEV nt 6012 to 6122 and 8514 to 8802)
sequences were also cloned into this vector for use as
negative controls. 32P-labeled RRE-C RNAs were gener-
ated by in vitro transcription of linearized plasmids (43).
35S-labeled Rev-C protein was in vitro translated (15, 19),
reacted with labeled target RNA, and precipitated with
specific anti-Rev-C peptide antibody as described in the
legend to Fig. 2. The RRE-C (/) probe/Rev-C protein com-
plex was specifically precipitated by anti-Rev-C sera only
in the presence of the Rev protein (Fig. 2A, lane 3). The
antisense RRE-C transcript, RRE-C (0), was not precipi-
tated (Fig. 2A, lane 4), indicating that Rev-C does not
interact with negative polarity RRE-C 7906-8110 transcripts
in these assays. This result is consistent with the obser-
vation that RRE-C function is orientation dependent; only
the sense (coding) orientation mediates Rev function in
boiled, quenched, and electrophoresed on 6% acrylamide/urea/TBE
gels. Lanes 1 and 6 are reactions containing mock in vitro-translated
protein (IVT); lanes 2, 3, 4, 7, and 8 contain Rev-C IVT. Lanes 1, 2, and
3 are reactions containing 32P-labeled, sense strand RRE-C (RRE-C(/));
lane 4 is a reaction with 32P-labeled, antisense strand RRE-C (RRE-
C(0)). Lanes 6, 7, and 8 are RNA IPs of a mixture of five different 32P-
labeled RNAs. Lanes 1, 3, 4, 6, and 8 are precipitated with anti-Rev-C
sera; lanes 2 and 7 are preimmune precipitated. Lane 5 contains the
unprecipitated probe mix so that the relative positions of each RNA on
the gel can be seen. The expected sizes of the transcripts are as
follows: visna env (244 nt); visna tat (323 nt); human actin (144 nt); Rev-
FIG. 2. (A) Immunoprecipitation of Rev-C/RRE-C complexes. Wildtype Cwildtype (505 nt). Lane M contains 32P-labeled single-stranded DNA
Rev-C was tested for its ability to specifically interact in vitro with markers, the size of which (in nucleotides) is shown to the left. The
RRE-C using an RNA immunoprecipitation assay. In this experiment, identity of each RNA is indicated to the right. (B) RNA/protein immuno-
[35S]methionine-labeled Rev-C was translated in vitro and then mixed precipitation control assays. 35S-labeled Rev-C (lanes 2, 3, 4, 5, 6, and
with various 32P-labeled, in vitro-transcribed RNAs. Protein/RNA binding 7) or mock (lane 1) in vitro translates were combined with 1.0 mg
reactions were assembled by combining 2 to 6 ml of in vitro-translated unlabeled RNA (lane 2, no RNA; lane 3, RRE-C (0) RNA; and lane 4,
protein, 2 to 4 ml (200,000 to 500,000 cpm) of 32P-labeled RNA, 1 ml RRE-C (/) RNA) and were precipitated with anti-Rev-C antibody (lanes
RNAsin (Promega), 1 ml 100 mM PMSF (phenylmethylsulfonyl flouride, 1–4). Lanes 5, 6, and 7 contain sequential immunoprecipitations in
Sigma Chemicals), 25 ml 21 RNA binding buffer (1.3% Nonidet P-40, which 35S-labeled Rev-C was combined with 1.0 mg of unlabeled RRE-
0.3 M NaCl, 0.02 M Tris, pH 7.5, 0.003 M MgCl2 ), and ddH2O to bring C (/) RNA and precipitated with Rev-C-specific sera (lane 5). The
the reaction volume up to 50 ml. After incubation at room temperature supernatant from this precipitation was then again subjected to anti-
for 30 min, 342 ml 11 RNA binding buffer and 4 ml of affinity-purified Rev-C immunoprecipitation (lane 6). The supernatant from the second
anti-Rev-C antisera were added to each reaction. The reactions were precipitation was then immunoprecipitated a third time (lane 7). All
incubated at 47 for 1 h. Protein/RNA complexes were precipitated by samples were immunoprecipitated using the RNA IP protocol and elec-
addition of Protein A–Sepharose beads (Pharmacia), incubation at 47 trophoresed on a 15% SDS–PAGE protein gel as described (15, 19).
for 1 h with gentle shaking, followed by centrifugation at 12,000g for 1 Lane M contains protein molecular weight markers. The location of Rev-
min at 47. The pellets were washed six times in cold 11 RNA binding C is indicated to the right; the sizes of the molecular weight markers in
buffer and resuspended in 100 ml of sequencing dye. Samples were kDa are shown to the left.
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cotransfection assays (15). In addition, mutational analy- RRE-C added to the reaction, which is indicative of a
specific, dose-dependent reaction between Rev-C andsis of the HIV RRE has shown that maintenance of the
correct secondary structure in mutant RREs is critical for the RRE (data not shown). Taken together these data
indicate that the observed reaction is specific and themaintaining Rev binding activity and, hence, Rev respon-
siveness (38, 44, 45). Since a negative sense RRE-C RNA immunoprecipitation method provides accurate quantita-
tive estimates of in vitro Rev/RRE interaction.would have a completely different sequence and second-
ary structure than the positive polarity RRE-C, it is not Comparison of visna virus Rev (Rev-V) and CAEV Rev
amino acid sequences indicates that they share very littlesurprising that the RRE-C (0) fails to bind Rev-C in vitro
(Fig. 2A) or to mediate Rev function in vivo (15). In Fig. 2A, homology except in two regions of their second exon
(Fig. 1B). Mutational analysis of Rev-V has demonstratedlanes 6 through 8, Rev-C was incubated with a mixture of
different RNAs (human actin, visna tat, visna env, CAEV that these domains have the same functions as in HIV
Rev (30). To determine the importance of these domainsrev, and RRE-C (/)). Anti-Rev-C sera precipitated only
complexes of Rev-C and RRE-C (/) RNA (Fig. 2A, lane to Rev-C function, mutations were constructed by poly-
merase chain reaction (PCR) amplification with overlap-8). These data demonstrate that the Rev protein interacts
specifically with its cognate RRE in vitro and suggest, ping oligonucleotides (Fig. 4A; 15, 19). Alteration of RR
to DL in the basic domain of Rev-C (pCMVRev-CRR-DL )when considered with the previously published cotrans-
fection experiments, that Rev-C mediates its effect by reduces trans-activating activity 20-fold (Fig. 4A; 15); de-
letion of the entire basic region (pCMVRev-Cdelta basic ) ab-interacting with the RRE (15).
Several additional control experiments were per- rogates Rev-C trans-activation (M. J. Saltarelli, personal
communication). Both Rev-CRR-DL and Rev-Cdelta basic bindformed to confirm that the RNA immunoprecipitation
assay is a quantitative measure of Rev-C/RRE-C interac- significantly less RRE-C RNA than does wildtype Rev-C
(Fig. 4B, lanes 3 and 4) in RNA IP assays. Quantitationtion. In Fig. 2B, 35S-labeled, in vitro-translated Rev-C pro-
tein was combined with excess (1 mg/reaction) unlabeled of six independent RRE-C binding assays indicates that
Rev-Cdelta basic and RR-DL bind 24- and 15-fold less RRE-C,RRE-C (/) RNA (lane 4), unlabeled RRE-C (0) RNA (lane
3), or no RNA (lane 2) and was then immunoprecipitated. respectively, than does wildtype Rev-C ( P value of 
0.005; Fig. 5A). These data demonstrate that the Rev-CAddition of RRE-C (/) does not change the amount of
Rev-C protein precipitated in the assay (lane 4) relative basic domain is required for efficient RRE-C binding in
vitro, similar to results obtained by mutational analysisto that precipitated in the presence of RRE-C (0) or in
the absence of RNA, demonstrating that RRE-C binding of the visna virus Rev protein (30).
The leucine domain mutants pCMVRev-Cdelta leu-rich anddoes not effect the ability of the antisera to immunopre-
cipitate the Rev-C protein. In addition, Rev-C was com- Rev-CLL-FV show greater than 40-fold reduced trans-acti-
vating activity in previous studies (Fig. 4A; 15). However,bined with excess unlabeled RRE-C (/) RNA and sub-
jected to multiple rounds of immunoprecipitation. Greater analysis of the RRE-C binding phenotype of Rev-C leu-
cine domain mutants indicates that the leucine domainthan 95% of the Rev-C protein present was precipitated
after the first addition of antisera (compare lane 5 to 6 has little influence on in vitro interaction with the RRE
(Fig. 4B, lanes 5,6, and 7). Two leucine domain mutants,and 7). These data indicate that the precipitations are
being performed in antibody excess and that the Rev-C/ Rev-CEE-DD and Rev-Cdelta leu-rich , bind the RRE as well as
wildtype Rev-C in this assay (Figs. 4B and 5A). Interest-RRE-C complexes are being quantitatively precipitated
from these reactions. ingly enough, the Rev-CLL-FV mutant has a small, but sig-
nificant ( P value of  0.05) and reproducible, deficiencyAs an independent confirmation that the observed in
vitro interaction between Rev-C and RRE-C is specific, in RRE-C binding compared to wildtype Rev-C
(Fig. 5A). It is possible that substitution of FV for LL atcompetition experiments were carried out (Fig. 3). In
these studies, various amounts of unlabeled competitor amino acid positions 100 and 102 of Rev-C causes a
conformational change in the protein that renders it lessRNAs were added to reactions that contained a constant
amount of both 32P-labeled RRE-C (/) RNA and Rev-C able to bind to the RRE. However, this small reduction
in RRE binding probably does not significantly con-protein. Addition of increasing amounts of unlabeled
RRE-C (/) competitor significantly reduces precipitation tribute to this mutant’s trans-activation defect, since
Rev-Cdelta leu-rich has full RRE-C binding activity but isof
32P-labeled RRE-C (/) RNA (Fig. 3, lanes 1 through 6);
inclusion of 25-fold excess unlabeled RRE-C (/) almost equally deficient as a trans-activator (Fig. 4A; 15). Further
experimentation is necessary to determine exactly howcompletely eliminates 32P-RRE-C precipitation compared
to the control (lanes 1 and 7). Addition of similar quanti- much the leucine-rich domain contributes to RRE binding
and whether the small reduction in RRE binding contri-ties of CAEV rev (Fig. 3, lanes 8–13) and RRE-C (0) (lanes
15–20) competitor RNAs has no effect on the Rev-C/RRE- butes to the massive loss of trans-activating activity
caused by the leucine domain LL-FV mutation.C (/) interaction. Dose response Rev-C/RRE-C binding
experiments indicate that the amount of RRE-C precipi- The Rev protein of HIV has been shown to form homo-
multimers in vitro; in addition, the ability to multimerizetated is directly proportional to the quantity of Rev-C or
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FIG. 3. Competition assays with unlabeled RRE-C (/) and irrelevant RNAs. RNA immunoprecipitation assays were performed as described in
Fig. 2 except that constant amounts of Rev-C and 32P-RRE-C (/) were incubated with increasing amounts of unlabeled competitor RNAs. The
unlabeled competitors used (RRE-C (/), RRE-C (0), or Rev-C RNAs) are indicated above each panel. The competitor/32P-RRE-C ratio is shown above
each lane (lanes 1, 8, and 15 are 25:1; lanes 2, 9, and 16 are 5:1; lanes 3, 10, and 17 are 1:1; lanes 4, 11, and 18 are 0.2:1; lanes 5, 12, and 19 are
0.04:1; lanes 6, 13, and 20 are 0.008:1; lanes 7, 14, and 21 contain no competitor RNA). Lane M contains 32P-labeled single-stranded DNA markers;
the size of each is shown to the left. The position of the RRE-C RNA is indicated to the right.
is thought to be required for in vivo function (25, 28). crosslinking, unlabeled Rev-C in vitro translate was
mixed with 35S-labeled, in vitro-translated visna Tat (Tat-Therefore, we used glutaraldehyde crosslinking assays
to examine formation of Rev-C multimers in vitro (46). V; an irrelevant protein which does not interact with Rev-
C), crosslinked, and immunoprecipitated with anti-visnaS35-labeled wildtype Rev-C was crosslinked, immunopre-
cipitated, and electrophoresed; these experiments re- Tat sera. No labeled complexes of any kind were precipi-
tated in these experiments, indicating that Rev-C andvealed the presence of a labeled protein band that is
expected size (38 kDa) of a Rev-C homodimer (Fig. 4C, Tat-V cannot be randomly crosslinked to each other un-
der these reaction conditions (data not shown). Theselane 2). Glutaraldehyde-crosslinked samples were also
electrophoresed without prior immunoprecipitation; the results suggest that the higher-molecular-weight forms
seen in crosslinked samples are not due to randomresults obtained were identical to those of immunopre-
cipitated samples (data not shown). Faint, higher-molec- crosslinking of 35S-labeled Rev-C to other proteins in the
rabbit reticulocyte lysate. These studies therefore dem-ular-weight, crosslinked products can also be seen when
crosslinked Rev-C protein is electrophoresed on longer onstrate that Rev-C can self-associate and form
multimers in vitro in the absence of its cognate RRE.(30 cm) SDS–PAGE gels (data not shown), indicating that
Rev-C can form higher-order multimers as well. These Since homomultimer formation of the HIV Rev protein
maps to the basic domain (28), we examined the capacityhigher-molecular-weight complexes differ in size from
each other by approximately 19 kDa, exactly what would of each Rev-C mutant to form multimers (Fig. 4C). All of
the mutants were able to form multimeric complexes inbe expected if they are Rev-C multimers. These higher-
molecular-weight forms appear only when Rev-C, and vitro; however, the Rev-Cdelta basic mutant was significantly
deficient in multimer formation compared to the rest ofnot mock, in vitro translates are crosslinked; in addition,
they are specifically immunoprecipitated by anti-Rev-C the mutants and wildtype Rev-C. Determination of the
monomer/dimer ratios of each mutant (Fig. 5B) clearlysera (Fig. 4C, lanes 1 and 2). Therefore, it is likely that
they are indeed multimers of Rev-C. However, it is possi- illustrates the difference between Rev-Cdelta basic and the
other Rev-C proteins. The fact that the Rev-Cdelta basicble that Rev-C monomers are being nonspecifically
crosslinked to some other 19-kDa protein present in the crosslinking reactions produce fewer multimeric com-
plexes (relative to the number of monomers present) thanin vitro translates. As a control for nonspecific protein
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FIG. 5. Quantitative comparison of mutant Rev-C protein RNA binding and multimerization phenotypes. Six independent experiments of the types
shown in Figs. 4B and 4C were executed; the results are presented in graphical form in A and B. (A) Quantitation of Rev-C wildtype and mutant
RNA immunoprecipitation experiments. The quantity of RRE-C or Rev-C precipitated was determined directly from RNA IP or SDS–PAGE gels using
a Molecular Dynamics Phosphorimager. Amounts of protein/RNA were calculated by subtracting the volume obtained in the same region of a
control immunoprecipitation lane from the volume of a particular protein/RNA band. The quantity of RNA bound by the Rev-C mutants (and wildtype
Rev-C) was normalized to the quantity of protein precipitated in matched control protein immune precipitates (Fig. 4B) so that RNA binding affinities
of the different proteins could be directly compared. The mean amount of RRE-C bound by each mutant (and wildtype) is indicated by the height
of the appropriate vertical column; standard errors of the mean for the values obtained for each set of experiments are shown by the error bars.
The identity of each Rev-C protein used is shown along the X-axis. The Y-axis is in arbitrary volume units. (B) Quantitation of Rev-C wildtype and
mutant crosslinking experiments. Monomer and multimer forms were quantitated by phosphorimager analysis; the amount of each present was
normalized according to the number of methionines present in each. The amount of ‘‘dimer’’ present in each lane was calculated by addition of the
quantities of all detectable multimeric forms present in a lane. In most cases, dimer was the predominant multimer form present. Monomer/dimer
ratios were calculated for each experiment; the mean values and the standard errors are shown in the graph as described in A. The identity of
each Rev-C protein used is indicated along the X-axis. SEM (standard error of the mean) was calculated using Minitab. T tests were used to
determine whether the differences between the mean activities of different mutants were significant. Bar graphs were made using Cricket Graph.
does wildtype indicates that the basic domain is required bly has little or no functional role during Rev-C in vitro
self-assembly.for efficient multimer formation in vitro. None of the leu-
cine domain mutants are significantly impaired in As discussed above, both Rev-CRR-DL and Rev-Cdelta basic
mutants are essentially nonfunctional as trans-activatorsmultimer formation compared to wildtype Rev-C (Figs. 4C
and 5B), which indicates that the leucine domain proba- (15). In addition, examination of the subcellular localiza-
FIG. 4. In vivo and in vitro functional analysis of Rev-C basic and leucine-rich domain mutants. (A) Sequence of Rev-C mutants. Asterisks below
the sequence of each mutant denote locations of amino acid mutations. The trans-activating activity of each mutant is shown to the right as fold
activation; these data are from previous studies (15). (B) In vitro analysis of the RRE binding phenotype of mutant Rev-C proteins. RNA IP analysis
was carried out as described using wildtype or mutant Rev-C IVTs and 32P-labeled RRE-C (/) in lanes 1 through 7 (or 32P-labeled RRE-C (0) in
lane 8). The Rev-C wildtype and mutant in vitro translates used in each reaction are shown above the appropriate lane. Matched control immunoprecip-
itations of the proteins used in the RNA IP reactions (identical reactions with no RNA added) were run on an SDS–PAGE gel; this gel is shown
below the RNA IP gel. The controls demonstrate that the lack of RRE precipitated by Rev-CRR-DL and Rev-Cdelta basic is not due to absence of protein
in the reactions. Lane M contains either single-stranded DNA or protein size markers as appropriate; the sizes in nucleotides or kDa are shown
to the left. The locations of RRE-C and Rev-C mutant proteins are indicated to the right. (C) In vitro multimer formation by the Rev-C mutants. In
vitro-translated Rev-C wildtype and mutant proteins were tested for their ability to form multimers in the absence of RRE-C using a glutaraldehyde
crosslinking assay (46). After crosslinking, Rev-C IVTs were immunoprecipitated using Rev-C-specific sera and electrophoresed on denaturing PAGE
gels (15, 19). Lanes 1 through 7 are crosslinking reactions of Rev-C mutants in the same order as in the RNA IP assay above. The location of Rev-
C monomer and dimer forms is indicated to the right; the sizes of the protein standards in lane M are denoted to the left.
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